Related Experiment Videos

Pseudomonas peritonitis in CAPD patients: characteristics and outcome of treatment

M K Chan1, P C Chan, I P Cheng

  • 1Department of Medicine, University of Hong Kong.

Insights

Pseudomonas peritonitis, a complication in dialysis patients, was treated effectively with ceftazidime and an aminoglycoside. Oral ofloxacin showed limited efficacy despite in vitro sensitivity.

Area of Science:

  • Nephrology
  • Infectious Diseases
  • Clinical Microbiology

Background:

  • Pseudomonas peritonitis is a serious complication in patients undergoing peritoneal dialysis.
  • Understanding treatment outcomes and risk factors is crucial for patient management.

Purpose of the Study:

  • To review episodes of Pseudomonas peritonitis in peritoneal dialysis patients.
  • To evaluate treatment efficacy and identify factors associated with repeat infections.

Main Methods:

  • Retrospective review of 25 episodes of Pseudomonas peritonitis over 5.5 years.
  • Analysis of demographic factors, infection history, treatment regimens, and outcomes.

Main Results:

  • Pseudomonas peritonitis represented 4.8% of all peritonitis episodes.
  • Exit site infection was more common in repeat infections.
  • An 80% cure rate was achieved with ceftazidime plus an aminoglycoside; oral ofloxacin was ineffective.

Conclusions:

  • Ceftazidime combined with an aminoglycoside is an effective treatment for Pseudomonas peritonitis.
  • Repeat peritonitis episodes may be associated with exit site infections.
  • Oral ofloxacin is not recommended for Pseudomonas peritonitis despite in vitro sensitivity.

Related Concept Videos